{"entity":{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","aka":[],"tldr":"Leads one of the largest breast medical oncology departments, and led the ribociclib trial in premenopausal women.","summary":"Debu Tripathy is Chair of the Department of Breast Medical Oncology at MD Anderson Cancer Center and editor-in-chief of the journal Cancer. A breast medical oncologist specialising in endocrine therapy and clinical trials, he was principal investigator of MONALEESA-7, the phase 3 trial of ribociclib plus endocrine therapy in premenopausal women with hormone-receptor-positive advanced breast cancer, and is a leader in HER2-directed and antibody-drug conjugate trials. His papers report the MONALEESA-7 trial in Lancet Oncology and its overall survival analysis in the New England Journal of Medicine. He leads one of the largest breast medical oncology departments, working on CDK4/6 and the oestrogen receptor.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Debu%20Tripathy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tripathy%20D%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Debu%20Tripathy"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":["cdk4-6","estrogen-receptor"],"drugs":["ribociclib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Breast Medical Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Breast cancer","Endocrine therapy","Clinical trials"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Debu%20Tripathy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tripathy%20D%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Debu%20Tripathy"}],"papers":[{"title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","journal":"Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(18)30292-4","doi":"10.1016/S1470-2045(18)30292-4"},{"title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/nejmoa1903765","doi":"10.1056/nejmoa1903765"}]},"route":"/people/debu-tripathy/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}]}}